Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
Provided herein are formulations, processes, solid forms and methods of use relating to 2-(tert-butylamino)-4-((1R,3R,4R)-3- hydroxy-4-methy1cydohexylamino)-pyrimidine-5-carboxamide (Compound I). Also provided herein is a method of preparing a compound of formula (iv) by contacting a compound of for...
Saved in:
Main Authors | , , , , , , , , , , , , , |
---|---|
Format | Patent |
Language | English |
Published |
24.02.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Provided herein are formulations, processes, solid forms and methods of use relating to 2-(tert-butylamino)-4-((1R,3R,4R)-3- hydroxy-4-methy1cydohexylamino)-pyrimidine-5-carboxamide (Compound I). Also provided herein is a method of preparing a compound of formula (iv) by contacting a compound of formula (iii) with R1NH2 in the presence of a base or Lewis acid. In another aspect, provided herein are methods for preparing certain compounds, including Compound I as described herein, as well as intermediates useful in such methods. In certain aspects, the solid forms of Compound I are useful for inhibiting a kinase in a cell expressing said kinase, for example JNK1 or JNK2. In another aspect, the solid forms of Compound I are useful for treating or preventing one or more disorders selected from interstitial pulmonary fibrosis, systemic sclerosis, scleroderma, chronic allograft nephropathy, antibody mediated rejection, or lupus. |
---|---|
AbstractList | Provided herein are formulations, processes, solid forms and methods of use relating to 2-(tert-butylamino)-4-((1R,3R,4R)-3- hydroxy-4-methy1cydohexylamino)-pyrimidine-5-carboxamide (Compound I). Also provided herein is a method of preparing a compound of formula (iv) by contacting a compound of formula (iii) with R1NH2 in the presence of a base or Lewis acid. In another aspect, provided herein are methods for preparing certain compounds, including Compound I as described herein, as well as intermediates useful in such methods. In certain aspects, the solid forms of Compound I are useful for inhibiting a kinase in a cell expressing said kinase, for example JNK1 or JNK2. In another aspect, the solid forms of Compound I are useful for treating or preventing one or more disorders selected from interstitial pulmonary fibrosis, systemic sclerosis, scleroderma, chronic allograft nephropathy, antibody mediated rejection, or lupus. |
Author | Hilgraf, Robert Beauchamps, Marie Georges Xu, Jean Boersen, Nathan Andrew Huang, Lianfeng Zhou, Nanfei Ferretti, Antonio Christian Li, Ying Kothare, Mohit Atul Zou, Daozhong Muslehiddinoglu, Jale Man, Hon-Wah Yong, Kelvin Hin-Yeong Nagy, Mark A |
Author_xml | – fullname: Beauchamps, Marie Georges – fullname: Zhou, Nanfei – fullname: Xu, Jean – fullname: Ferretti, Antonio Christian – fullname: Zou, Daozhong – fullname: Huang, Lianfeng – fullname: Muslehiddinoglu, Jale – fullname: Li, Ying – fullname: Yong, Kelvin Hin-Yeong – fullname: Kothare, Mohit Atul – fullname: Nagy, Mark A – fullname: Man, Hon-Wah – fullname: Boersen, Nathan Andrew – fullname: Hilgraf, Robert |
BookMark | eNqFTsuKwjAU7cJZ-PoFybJCL6jV6lYGZVZudOVGYnJLA0luuUmh-Zb5WTvD4HZWB857ko08eRxn31eyRoua2AVBtdhAHpEjPLuYrHTG0xK2kOdrLkoutryEEpqkmfo08A5jk6xKylKD_TvQJjbOaOMRdqAkP6kfFI2FUORaCiYa8kHEBhmHTem1-Gki_XthoA2LLuAs-6ilDTj_w2m2OJ9un1-ALT0wtFKhx_i43PfVelUdjuW_hhdpjlIE |
ContentType | Patent |
DBID | EVB |
DatabaseName | esp@cenet |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Sciences |
ExternalDocumentID | NZ761068A |
GroupedDBID | EVB |
ID | FETCH-epo_espacenet_NZ761068A3 |
IEDL.DBID | EVB |
IngestDate | Fri Jul 19 14:23:24 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-epo_espacenet_NZ761068A3 |
Notes | Application Number: NZ20150761068 |
OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230224&DB=EPODOC&CC=NZ&NR=761068A |
ParticipantIDs | epo_espacenet_NZ761068A |
PublicationCentury | 2000 |
PublicationDate | 20230224 |
PublicationDateYYYYMMDD | 2023-02-24 |
PublicationDate_xml | – month: 02 year: 2023 text: 20230224 day: 24 |
PublicationDecade | 2020 |
PublicationYear | 2023 |
RelatedCompanies | SIGNAL PHARMACEUTICALS LLC |
RelatedCompanies_xml | – name: SIGNAL PHARMACEUTICALS LLC |
Score | 3.450088 |
Snippet | Provided herein are formulations, processes, solid forms and methods of use relating to 2-(tert-butylamino)-4-((1R,3R,4R)-3-... |
SourceID | epo |
SourceType | Open Access Repository |
SubjectTerms | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
Title | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230224&DB=EPODOC&locale=&CC=NZ&NR=761068A |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV3dT8IwEG8Qjfqm-P1B9mAWSGicrBvjYTEyIMTEQRQN4YV0ayckZCPbiOxv8Z_1Wgf6wltzl7XdNbe77n53h9AdMTRuNRoaZjrTMTEDA1uc6tgkLKBBUzMtLtEWrtl7J88jY1RAn-tcGFkn9EsWRwSN8kHfU_m9Xvz9xGpLbGVy782AFD12h3ZbzW_H4E-DSVLbLbsz6Lf7juo4tjtW3Vcbbuuw7tMO2gUfuiFUofPREikpi__2pHuE9gYwVZgeowIPS-jAWbddK6H9lzzaDcNc8ZIT9P0WzWdMER5mokSBUscVEczH3jLN4ExnYVTFBFcqD3FNj2skrmIdTzMmMCpAF22is7mf-fNoylebBxaZ6OkFxotjA_s09qIVcBivKQJovkZzKcJF5LAmDZny23BabkGGGJRlwk9RudsZOj0MbznZyHPijnNp6GeoGEYhv0CK1WSBr3kBMagIpRnUE4VrdMrrwKBN8xKdb5nkaivnGh2KI5EJ4OQGFdN4yW_BhKdeWYr_B4-FpBU |
link.rule.ids | 230,309,783,888,25576,76876 |
linkProvider | European Patent Office |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1LT8JAEN4gGvGm-H5gD6aBhI2Vbks5NEZaCCoUomgIF9LHVkhIS9oS6W_xzzq7FvTibTOT7m53Mp3ZzjczCN0QRaJavS5hT_ZkTFRfwRq1ZawSz7f9hqRqlKMtLLXzRp5GyiiHPta5MLxO6Ccvjgga5YK-J_x7vfj9iWVybGV868yAFN63h7opZrdj8KfBJIlmU28N-mbfEA1Dt8ai9aLDbR3WfdhC2-Bf15kqtN6bLCVl8deetPfRzgCmCpIDlKNBERWMddu1ItrtZdFuGGaKFx-ir9dwPvME5mHGQugLNVxmwXzsLJMUZDoLwgomuFy-i6pyVCVRBct4mnoMowJ01iY6nbupOw-ndLV5YJGynl5gvChWsGtHTrgCjkerAgOar9FcAnMRKaxpB57w03Cab4GHGIRlTI9Qqd0aGh0MbznZnOfEGmenIR-jfBAG9BQJWsPzXcnxiWKzUJpiO6xwjWzTGjDshnqGTv6Z5PxfzjUqdIa97qT7aD1foD0mHp4MTi5RPomW9ArMeeKUuCi-AXAKpwg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Solid+forms+of+2-%28tert-butylamino%29-4-%28%281r%2C3r%2C4r%29-3-hydroxy-4-methylcyclohexylamino%29-pyrimidine-5-carboxamide%2C+compositions+thereof+and+methods+of+their+use&rft.inventor=Beauchamps%2C+Marie+Georges&rft.inventor=Zhou%2C+Nanfei&rft.inventor=Xu%2C+Jean&rft.inventor=Ferretti%2C+Antonio+Christian&rft.inventor=Zou%2C+Daozhong&rft.inventor=Huang%2C+Lianfeng&rft.inventor=Muslehiddinoglu%2C+Jale&rft.inventor=Li%2C+Ying&rft.inventor=Yong%2C+Kelvin+Hin-Yeong&rft.inventor=Kothare%2C+Mohit+Atul&rft.inventor=Nagy%2C+Mark+A&rft.inventor=Man%2C+Hon-Wah&rft.inventor=Boersen%2C+Nathan+Andrew&rft.inventor=Hilgraf%2C+Robert&rft.date=2023-02-24&rft.externalDBID=A&rft.externalDocID=NZ761068A |